ext-Generation Therapy for NK/T-cell lymphoma in East Asia: a multicenter retrospective study in Japan for the next step
Not Applicable
- Conditions
- Extranodal NK/T-cell lymphoma, nasal type (ENKL)
- Registration Number
- JPRN-UMIN000046300
- Lead Sponsor
- Mie University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 368
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with one or more of the following are excluded. 1. Patients who were diagnosed as not ENKL based on diagnosis-related information or central pathology review 2. Patients who refused to consent to opt-out
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival of ENKL patients who received next-generation treatment in 2014-2021 at participating institutes
- Secondary Outcome Measures
Name Time Method 1. Clinical features, treatment, toxicity profile, and risk factors affecting survival of ENKL patients who received next-generation treatment in 2014-2021 at participating institutes 2. Clinical features, treatment, toxicity profile, and prognosis of ENKL patients diagnosed in 2014-2021 at participating institutions and their annual transition 3. Construction of ENKL patient database combined with the dataset of NKEA Part A